Doctors are encountering BPC-157 in patient histories more often, even though the peptide remains unapproved. Researchers searching 15.2 million electronic medical records identified 1,039 patients with confirmed documentation of BPC-157 use. Their retrospective preprint, posted in early September, reports that newly documented users rose from four in the first quarter of 2020 to 134 in the first quarter of 2026.
That is roughly a 33-fold increase between those two quarters. It is not a measure of total US use, a national prevalence estimate, or proof that the peptide works. The researchers could count only people whose use appeared in clinical records and met their confirmation criteria. Someone buying a vial online and never telling a clinician would not necessarily appear in the data.
What the records capture
The study draws its value from a large set of real clinical notes rather than a survey of people who chose to answer questions about peptide use. Yet the denominator is still a health-record population, not all consumers. Medical documentation may become more common as clinicians learn to ask about unapproved products. That could contribute to the rise alongside any real increase in use. The authors' quarterly counts show a striking change in recorded exposure; they cannot separate those explanations completely.
For only 205 of the 1,039 confirmed users was a source of BPC-157 recorded. Within that smaller group, 74 were linked to compounding pharmacies and 71 to gray-market suppliers, according to the preprint. Those figures should not be projected onto the other 834 people whose source was not documented. They do show why a single label such as “BPC-157 user” can conceal very different acquisition routes and product-quality questions.
The records also complicate any simple claim about benefits or harms. Roughly half the identified patients used another therapeutic agent, making it difficult to attribute later symptoms or improvements to BPC-157 alone. This was an observational analysis of documented use, not a randomized trial that assigned a known product and measured a prespecified clinical outcome. The manuscript is a preprint and had not undergone peer review at the time of publication.
For readers, the important distinction is between evidence that a product is being used and evidence that it is safe or effective. The dataset supports the first point. It does not settle the second. Our BPC-157 pharmacology guide separates proposed effects from human clinical evidence, while the guide to research-peptide quality checks explains why uncertain sourcing adds a second problem to uncertain efficacy.
Clinicians who encounter the peptide in a patient's history can ask what product was used, where it came from and whether any symptoms followed. Those details are more useful than treating the headline growth figure as a safety verdict. The study's clearest finding is that clinical conversations about BPC-157 are increasing faster than reliable answers about what its use does to people.
